Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

241 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection.
Matthews GV, Bhagani S, Van der Valk M, Rockstroh J, Feld JJ, Rauch A, Thurnheer C, Bruneau J, Kim A, Hellard M, Shaw D, Gane E, Nelson M, Ingiliz P, Applegate TL, Grebely J, Marks P, Martinello M, Petoumenos K, Dore GJ; REACT study group; Protocol Steering Committee; Coordinating Centre; Site Principal Investigators. Matthews GV, et al. J Hepatol. 2021 Oct;75(4):829-839. doi: 10.1016/j.jhep.2021.04.056. Epub 2021 May 21. J Hepatol. 2021. PMID: 34023350 Free PMC article.
HIV and hepatitis C coinfection.
Matthews GV, Dore GJ. Matthews GV, et al. J Gastroenterol Hepatol. 2008 Jul;23(7 Pt 1):1000-8. doi: 10.1111/j.1440-1746.2008.05489.x. J Gastroenterol Hepatol. 2008. PMID: 18707597 Review.
Treatment of acute HCV infection.
Grebely J, Matthews GV, Dore GJ. Grebely J, et al. Among authors: matthews gv. Nat Rev Gastroenterol Hepatol. 2011 May;8(5):265-74. doi: 10.1038/nrgastro.2011.32. Epub 2011 Mar 22. Nat Rev Gastroenterol Hepatol. 2011. PMID: 21423258 Review.
Direct-acting antivirals for acute HCV: how short can we go?
Martinello M, Grebely J, Matthews GV. Martinello M, et al. Among authors: matthews gv. Lancet Gastroenterol Hepatol. 2017 May;2(5):316-318. doi: 10.1016/S2468-1253(17)30043-2. Epub 2017 Feb 28. Lancet Gastroenterol Hepatol. 2017. PMID: 28397692 No abstract available.
Hepatitis C treatment as prevention: evidence, feasibility, and challenges.
Hajarizadeh B, Grebely J, Martinello M, Matthews GV, Lloyd AR, Dore GJ. Hajarizadeh B, et al. Among authors: matthews gv. Lancet Gastroenterol Hepatol. 2016 Dec;1(4):317-327. doi: 10.1016/S2468-1253(16)30075-9. Epub 2016 Nov 10. Lancet Gastroenterol Hepatol. 2016. PMID: 28404202 Review.
Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial.
Grebely J, Dalgard O, Conway B, Cunningham EB, Bruggmann P, Hajarizadeh B, Amin J, Bruneau J, Hellard M, Litwin AH, Marks P, Quiene S, Siriragavan S, Applegate TL, Swan T, Byrne J, Lacalamita M, Dunlop A, Matthews GV, Powis J, Shaw D, Thurnheer MC, Weltman M, Kronborg I, Cooper C, Feld JJ, Fraser C, Dillon JF, Read P, Gane E, Dore GJ; SIMPLIFY Study Group. Grebely J, et al. Among authors: matthews gv. Lancet Gastroenterol Hepatol. 2018 Mar;3(3):153-161. doi: 10.1016/S2468-1253(17)30404-1. Epub 2018 Jan 6. Lancet Gastroenterol Hepatol. 2018. PMID: 29310928 Free article. Clinical Trial.
Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study.
Cunningham EB, Amin J, Feld JJ, Bruneau J, Dalgard O, Powis J, Hellard M, Cooper C, Read P, Conway B, Dunlop AJ, Norton B, Litwin AH, Hajarizadeh B, Thurnheer MC, Dillon JF, Weltman M, Shaw D, Bruggmann P, Gane E, Fraser C, Marks P, Applegate TL, Quiene S, Siriragavan S, Matthews GV, Dore GJ, Grebely J; SIMPLIFY study group. Cunningham EB, et al. Among authors: matthews gv. Int J Drug Policy. 2018 Dec;62:14-23. doi: 10.1016/j.drugpo.2018.08.013. Epub 2018 Oct 22. Int J Drug Policy. 2018. PMID: 30352330 Clinical Trial.
241 results